Terms ending in 2031
Every in-force patent on Irm LLC's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,064,918 | Mesenchymal Stem Cell Differentiation In force · High confidence | Novartis International Pharmaceuticals Ltd. | In force | High confidence | |
| US 9,580,426 | Compounds That Expand Hematopoietic Stem Cells In force · High confidence | The Scripps Research Institute | In force | High confidence | |
| US 9,365,506 | Compounds and Compositions as TLR2 Agonists In force · High confidence | Irm LLC | In force | High confidence | |
| US 9,314,464 | Compounds and Compositions as Protein Kinase Inhibitors In force · High confidence | Array Biopharma, Inc. | In force | High confidence | |
| US 8,557,801 | Compounds and Compositions Useful for the Treatment of Parasitic Diseases In force · High confidence | Novartis AG | In force | High confidence | |
| US 8,808,703 | Compounds (Cystein Based Lipopeptides) and Compositions as TLR2 Agonists Used for Treating Infections, Inflammations, Respiratory Diseases Etc. In force · High confidence | Novartis AG | In force | High confidence | |
| US 10,098,949 | Adsorption of Immunopotentiators to Insoluble Metal Salts In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence | |
| US 9,315,530 | Adsorption of Immunopotentiators to Insoluble Metal Salts In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Irm LLC.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.